Skip to main content

Table 3 Pharmacokinetics and administration of vancomycin

From: Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study

Characteristic

All patients

(N = 45)

30-day all-cause mortality group

(N = 12)

Survival group

(N = 33)

P-value

Vancomycin trough concentration (μg/mL)a

15 (9.7–22.3)

20.5 (13.4–26.7)

14.6 (9.3–19.2)

0.022i)

Frequency of vancomycin administration until the first measurement of the vancomycin trough concentrationa

3 (3–5)

3 (3–5)

3 (3–5)

0.36i)

Vancomycin AUC24 (μg/mL·h)a

665 (444–898)

721 (380–860)

651 (462–952)

0.77i)

Vancomycin AUC24/MIC ratioa

725 (450–1186)

792 (332–1040)

707 (450–1304)

0.76i)

Number of cases with failure to achieve a vancomycin AUC24/MIC ratio ≤ 389

8 (17.8%)

3 (25.0%)

5 (15.2%)

0.66ii)

Duration of vancomycin administration (days)a

11.5 (7.0–16.5)

7 (4.0–11)

15 (10–25)

< 0.001i)

End of vancomycin administration due to death

8

8

0

Vancomycin used for empirical therapy

29 (64.4%)

9 (75.0%)

20 (60.6%)

0.49ii)

Duration from blood culture collection to vancomycin administration (days)a

3 (1–4)

1 (1–4)

3 (1–4)

0.30i)

  1. AUC24 estimated area under the curve from 0 to 24 h, MIC minimum inhibitory concentration
  2. i) Mann-Whitney U test, ii) Fisher’s exact test
  3. aExpressed as medians and interquartile ranges (IQR)
  4. The P-value was calculated by processing the comparison between the 30-day all-cause mortality group and the survival group by an appropriate statistical analysis